A Novel, Multi-Target Natural Drug Candidate, Matrine, Improves Cognitive Deficits in Alzheimer’s Disease Transgenic Mice by Inhibiting Aβ Aggregation and Blocking the RAGE/Aβ Axis

The Selective BACE1 Inhibitor VIa Reduces Amyloid-β Production in Cell and Mouse Models of Alzheimer's Disease

(2018) Xiaorui Cheng et al.   JOURNAL OF ALZHEIMERS DISEASE

Ferulic Acid Inhibits the Transition of Amyloid-β42 Monomers to Oligomers but Accelerates the Transition from Oligomers to Fibrils

(2018) Lili Cui et al.   JOURNAL OF ALZHEIMERS DISEASE

Treating transgenic Alzheimer mice with a β-secretase inhibitor, what have we learned?

(2016) Jordan Tang et al.   Aging-US

Novel β-amyloid aggregation inhibitors possessing a turn mimic

(2015) Yoshio Hamada et al.   BIOORGANIC & MEDICINAL CHEMISTRY LETTERS

Advances in Alzheimer’s Disease Drug Development

(2015) Michael S Rafii et al.   BMC Medicine

Alzheimer-associated A  oligomers impact the central nervous system to induce peripheral metabolic deregulation

(2015) J. R. Clarke et al.   EMBO Molecular Medicine

Matrine protects neuro-axon from CNS inflammation-induced injury

(2015) Quan-Cheng Kan et al.   EXPERIMENTAL AND MOLECULAR PATHOLOGY

Amyloid precursor protein metabolism and inflammation markers in preclinical Alzheimer disease

(2015) Daniel Alcolea et al.   NEUROLOGY

Alzheimer neurodegeneration, autophagy, and Abeta secretion: The ins and outs (comment on DOI 10.1002/bies.201400002)

(2014) Ralph A. Nixon   BIOESSAYS

Lessons from a Failed γ-Secretase Alzheimer Trial

(2014) Bart De Strooper   CELL

Structure-Activity Relationships for a Series of Compounds that Inhibit Aggregation of the Alzheimer's Peptide, Aβ42

(2014) Angela F. McKoy et al.   Chemical Biology & Drug Design

Dual Inhibitors of β-Amyloid Aggregation and Acetylcholinesterase as Multi-Target Anti-Alzheimer Drug Candidates

(2014) Elisabet Viayna et al.   CURRENT TOPICS IN MEDICINAL CHEMISTRY

Upregulation of immunomodulatory molecules by matrine treatment in experimental autoimmune encephalomyelitis

(2014) Nan Liu et al.   EXPERIMENTAL AND MOLECULAR PATHOLOGY

Clinical trials and late-stage drug development for Alzheimer's disease: an appraisal from 1984 to 2014

(2014) L. S. Schneider et al.   JOURNAL OF INTERNAL MEDICINE

Molecular basis of nitrate uptake by the plant nitrate transporter NRT1.1

(2014) Joanne L. Parker et al.   NATURE

Clinical trial of an inhibitor of RAGE-A  interactions in Alzheimer disease

(2014) D. Galasko et al.   NEUROLOGY

In SilicoDesign of BACE1 Inhibitor for Alzheimer’s Disease by Traditional Chinese Medicine

(2014) Hung-Jin Huang et al.   Biomed Research International

Amyloid-β and Tau

(2014) George S. Bloom   JAMA Neurology

Trp358 is a key residue for the multiple catalytic activities of multifunctional amylase OPMA-N from Bacillus sp. ZW2531-1

(2013) Hao Cao et al.   APPLIED MICROBIOLOGY AND BIOTECHNOLOGY

Design, synthesis and anti-Alzheimer properties of dimethylaminomethyl-substituted curcumin derivatives

(2013) Lei Fang et al.   BIOORGANIC & MEDICINAL CHEMISTRY LETTERS

Multi-target action of the novel anti-Alzheimer compound CHF5074: in vivo study of long term treatment in Tg2576 mice

(2013) Sandra Sivilia et al.   BMC NEUROSCIENCE

Receptor binding by a ferret-transmissible H5 avian influenza virus

(2013) Xiaoli Xiong et al.   NATURE

Aβ-independent processes—rethinking preclinical AD

(2013) Gaël Chételat   Nature Reviews Neurology

Inhibition of amyloid beta-induced synaptotoxicity by a pentapeptide derived from the glycine zipper region of the neurotoxic peptide

(2013) Christian Peters et al.   NEUROBIOLOGY OF AGING

Molecular interactions of Alzheimer amyloid-β oligomers with neutral and negatively charged lipid bilayers

(2013) Xiang Yu et al.   PHYSICAL CHEMISTRY CHEMICAL PHYSICS

Amyloid β-Peptide 25–35 Self-Assembly and Its Inhibition: A Model Undecapeptide System to Gain Atomistic and Secondary Structure Details of the Alzheimer’s Disease Process and Treatment

(2012) Marina Naldi et al.   ACS Chemical Neuroscience

Inhibition of amyloid-beta peptide aggregation rescues the autophagic deficits in the TgCRND8 mouse model of Alzheimer disease

(2012) Aaron Y. Lai et al.   BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR BASIS OF DISEASE

The γ-secretase inhibitor 2-[(1R)-1-[(4-chlorophenyl)sulfonyl](2,5-difluorophenyl) amino]ethyl-5-fluorobenzenebutanoic acid (BMS-299897) alleviates Aβ1–42 seeding and short-term memory deficits in the Aβ25–35 mouse model of Alzheimer's disease

(2012) Johann Meunier et al.   EUROPEAN JOURNAL OF PHARMACOLOGY

Is RAGE still a therapeutic target for Alzheimer’s disease?

(2012) Richard J Deane   Future Medicinal Chemistry

A Novel Inhibitor of Amyloid β (Aβ) Peptide Aggregation

(2012) Angela Fortner McKoy et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Tannic Acid Is a Natural β-Secretase Inhibitor That Prevents Cognitive Impairment and Mitigates Alzheimer-like Pathology in Transgenic Mice

(2012) Takashi Mori et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

A multimodal RAGE-specific inhibitor reduces amyloid β–mediated brain disorder in a mouse model of Alzheimer disease

(2012) Rashid Deane et al.   JOURNAL OF CLINICAL INVESTIGATION

Involvement of formyl peptide receptors in receptor for advanced glycation end products (RAGE) - and amyloid beta 1-42-induced signal transduction in glial cells

(2012) Alexander Slowik et al.   Molecular Neurodegeneration

Resveratrol Inhibits the Formation of Multiple-Layered β-Sheet Oligomers of the Human Islet Amyloid Polypeptide Segment 22–27

(2011) Ping Jiang et al.   BIOPHYSICAL JOURNAL

Antiinflammatory effects of matrine in LPS-induced acute lung injury in mice

(2011) Bo Zhang et al.   EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES

Aβ-Degrading Enzymes: Potential for Treatment of Alzheimer Disease

(2011) James Scott Miners et al.   JOURNAL OF NEUROPATHOLOGY AND EXPERIMENTAL NEUROLOGY

PF-04494700, an Oral Inhibitor of Receptor for Advanced Glycation End Products (RAGE), in Alzheimer Disease

(2010) Marwan N. Sabbagh et al.   ALZHEIMER DISEASE & ASSOCIATED DISORDERS

Soluble RAGE: Therapy and biomarker in unraveling the RAGE axis in chronic disease and aging

(2010) Shi Fang Yan et al.   BIOCHEMICAL PHARMACOLOGY

The 1.5 Å Crystal Structure of Human Receptor for Advanced Glycation Endproducts (RAGE) Ectodomains Reveals Unique Features Determining Ligand Binding

(2010) HaJeung Park et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

A Noncompetitive BACE1 Inhibitor TAK-070 Ameliorates A  Pathology and Behavioral Deficits in a Mouse Model of Alzheimer's Disease

(2010) H. Fukumoto et al.   JOURNAL OF NEUROSCIENCE

Alzheimer's disease: clinical trials and drug development

(2010) Francesca Mangialasche et al.   LANCET NEUROLOGY

Structural conversion of neurotoxic amyloid-β1–42 oligomers to fibrils

(2010) Mahiuddin Ahmed et al.   NATURE STRUCTURAL & MOLECULAR BIOLOGY

AGEs/RAGE complex upregulates BACE1 via NF-κB pathway activation

(2010) Michela Guglielmotto et al.   NEUROBIOLOGY OF AGING

RAGE regulates BACE1 and Aβ generation via NFAT1 activation in Alzheimer’s disease animal model

(2009) H. J. Cho et al.   FASEB JOURNAL

RAGE-dependent signaling in microglia contributes to neuroinflammation, Aβ accumulation, and impaired learning/memory in a mouse model of Alzheimer’s disease

(2009) Fang Fang et al.   FASEB JOURNAL

Impact of matrine on inflammation related factors in rat intestinal microvascular endothelial cells

(2009) Zhanwei Suo et al.   JOURNAL OF ETHNOPHARMACOLOGY

Structure of the Amyloid-β (1−42) Monomer Absorbed To Model Phospholipid Bilayers: A Molecular Dynamics Study

(2009) Charles H. Davis et al.   JOURNAL OF PHYSICAL CHEMISTRY B

RAGE-mediated signaling contributes to intraneuronal transport of amyloid-  and neuronal dysfunction

(2009) K. Takuma et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Hippocampal RAGE immunoreactivity in early and advanced Alzheimer's disease

(2008) Miles C. Miller et al.   BRAIN RESEARCH